ABL Diagnostics, a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories, has announced the expansion of its network of exclusive distributors to offer the DeepChek® technology to laboratories performing infectious diseases genotyping. The DeepChek® technology is offered via unique Sanger & Next Generation Sequencing (“NGS”) based assays and a suite of software reporters and related databases.
The company has a network of local professional partners covering 47 countries in Africa, Asia, Europe, the Middle East and South America, enabling them to offer end-to-end solutions covering both Capillary Electrophoresis (SANGER) and Next Generation Sequencing (NGS) workflows to small, medium and high throughput laboratories.
“We are extremely pleased to rely on a growing number of local distributors, trained on the ABL Diagnostics technology and able to offer innovative assays and end-to end solutions to microbiology labs on a worldwide basis” said Dimitri Gonzalez, Head of Diagnostics at ABL Diagnostics.
Christopher Busuttil, Chief Visionary Officer at Evolve Ltd (Malta) said: “Partnering with ABL to provide critical quality and dependable diagnostic tests on time and at the right price in these times of great financial instabilities and logistical problems was no easy feat. With determination and a focus on our philosophy of making a positive impact on society through science, the decision to exceed customer requirements and expectations was easier, even if it meant putting less focus on immediate financial returns. We are all grateful to do our part in combating Covid-19 and to continue being a key stakeholder in patients’ health.”
ABL Diagnostics is also strengthening its commercial presence in various Western European countries (France, Spain, Germany, Sweden, Denmark…) and has established collaborations and customers adopting the DeepChek® technology for various applications (HIV, RVS, BKV, Viral Hepatitis…).
The company is planning to strengthen its team to actively start operations in Asia and in the USA in 2024.
Today, ABL Diagnostics has announced the expansion of its network of exclusive distributors, enabling them to offer the DeepChek® technology to laboratories performing infectious diseases genotyping. The DeepChek® technology is offered via unique Sanger & Next Generation Sequencing (“NGS”) based assays and a suite of software reporters and related databases. This technology covers one of the largest portfolio of microbiology applications, with a primary focus on HIV, SARS-CoV-2, Tuberculosis, Viral Hepatitis, 16s/18s RNA, and other viral and bacterial targets.
The company has a network of local professional partners covering 47 countries in Africa, Asia, Europe, the Middle East and South America, enabling them to offer end-to-end solutions covering both Capillary Electrophoresis (SANGER) and Next Generation Sequencing (NGS) workflows to small, medium and high throughput laboratories.
Dimitri Gonzalez, Head of Diagnostics at ABL Diagnostics said: “We are extremely pleased to rely on a growing number of local distributors, trained on the ABL Diagnostics technology and able to offer innovative assays and end-to end solutions to microbiology labs on a worldwide basis.”
Christopher Busuttil, Chief Visionary Officer at Evolve Ltd (Malta) added: “Partnering with ABL to provide critical quality and dependable diagnostic tests on time and at the right price in these times of great financial instabilities and logistical problems was no easy feat. With determination and a focus on our philosophy of making a positive impact on society through science, the decision to exceed customer requirements and expectations was easier, even if it meant putting less focus on immediate financial returns. We are all grateful to do our part in combating Covid-19 and to continue being a key stakeholder in patients’ health.”
ABL Diagnostics is also strengthening its commercial presence in various Western European countries (France, Spain, Germany, Sweden, Denmark…) and has established collaborations and customers adopting the DeepChek® technology for various applications (HIV, RVS, BKV, Viral Hepatitis…). The company is planning to strengthen its team to actively start operations in Asia and in the USA in 2024.
ABL Diagnostics, a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories, has expanded its network of exclusive distributors to offer the DeepChek® technology for infectious diseases genotyping.
The DeepChek® technology is a suite of Sanger & NGS assays and software systems that is offered via
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.